List of Excipients in Branded Drug DASH CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE

Generic Drugs Containing DASH CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE

Company	Ingredient	NDC	Excipient
Cardinal Health 107 LLC	chlorhexidine gluconate 0.12% oral rinse	55154-1980	ALCOHOL
Cardinal Health 107 LLC	chlorhexidine gluconate 0.12% oral rinse	55154-1980	FD&C BLUE NO. 1
Cardinal Health 107 LLC	chlorhexidine gluconate 0.12% oral rinse	55154-1980	GLYCERIN
Cardinal Health 107 LLC	chlorhexidine gluconate 0.12% oral rinse	55154-1980	PEG-40 SORBITAN DIISOSTEARATE
Cardinal Health 107 LLC	chlorhexidine gluconate 0.12% oral rinse	55154-1980	PEPPERMINT OIL

What are the Most Frequently-Used Excipients in DASH CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE?

# Of NDCs	Excipient
3	ALCOHOL
3	FD&C BLUE NO. 1
3	GLYCERIN
3	PEG-40 SORBITAN DIISOSTEARATE
3	PEPPERMINT OIL

DASH Chlorhexidine Gluconate 0.12% Oral Rinse: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 13, 2026

DASH Chlorhexidine Gluconate 0.12% Oral Rinse is a prescription generic oral solution used to reduce gingival inflammation and microbial burden in patients with gingivitis. Its commercial opportunity is driven by low manufacturing complexity, limited patent barriers, recurring dental demand, and formulation differentiation through alcohol-free delivery, flavor, packaging, and institutional supply formats. The principal technical risk is excipient compatibility with chlorhexidine, a cationic antimicrobial that can be inactivated or precipitated by anionic ingredients.

What is DASH Chlorhexidine Gluconate 0.12% Oral Rinse?

DASH Chlorhexidine Gluconate 0.12% Oral Rinse contains chlorhexidine gluconate at 0.12% w/v, equivalent to 1.2 mg/mL of chlorhexidine gluconate solution. The product is intended for prescription use in the management of gingivitis as an adjunct to dental care.

Public product labeling identifies the dosage form as an oral rinse and lists inactive ingredients consistent with the established chlorhexidine gluconate oral-rinse platform:

Attribute	Product information
Active ingredient	Chlorhexidine gluconate
Strength	0.12%
Dosage form	Oral solution/oral rinse
Route	Oral, expectorated
Primary indication	Gingivitis
Regulatory category	Prescription drug
Reference product	Peridex chlorhexidine gluconate oral rinse
Main formulation issue	Compatibility of cationic chlorhexidine with excipients and packaging
Biosimilar relevance	None; this is a small-molecule drug

The typical reference formulation contains purified water, alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium saccharin, and FD&C Blue No. 1. The exact excipient composition and manufacturing controls for the DASH product should be taken from its current FDA-approved labeling and approved chemistry, manufacturing, and controls documentation. (DailyMed, n.d.; U.S. Food and Drug Administration [FDA], n.d.-a)

What excipients are used in chlorhexidine gluconate 0.12% oral rinse?

The established excipient system is designed to maintain chlorhexidine solubility, improve mouthfeel, provide flavor, and support product identification.

Excipient class	Typical function	Commercial and technical considerations
Purified water	Vehicle	Must meet pharmaceutical water and microbial-quality requirements
Alcohol, where used	Solvent and sensory modifier	Can improve solubilization but creates taste, irritation, and alcohol-free positioning concerns
Glycerin	Humectant and mouthfeel agent	Can reduce harshness and improve viscosity
PEG-40 sorbitan diisostearate	Solubilizer for flavor components	Requires control of grade, peroxide value, and lot-to-lot sensory variability
Flavor	Taste masking	The highest-value differentiation lever, but also a major source of stability and patient-acceptance risk
Sodium saccharin	Sweetener	Low-cost, effective, but may create an artificial aftertaste
FD&C Blue No. 1	Colorant	Supports brand recognition and product identification; unnecessary for a clear or color-free version

The formulation should avoid excipients that carry anionic functionality unless compatibility has been demonstrated. Chlorhexidine is cationic and may interact with anionic surfactants, soaps, phosphate-rich systems, carboxylated polymers, and certain flavor or coloring components. Toothpaste residues, particularly sodium lauryl sulfate, can reduce chlorhexidine substantivity or interfere with antimicrobial performance. The labeling for chlorhexidine oral rinse instructs patients to use the rinse after brushing and to avoid rinsing with water or consuming food and beverages immediately after use. (FDA, n.d.-b)

How should an excipient strategy be designed for DASH chlorhexidine rinse?

The strongest strategy is to preserve the established chlorhexidine formulation platform while creating a controlled differentiation pathway.

1. Maintain a compatibility-first formulation

The initial formulation should prioritize:

• Chlorhexidine assay and uniformity
• Absence of precipitation or haze
• pH stability
• Microbial quality
• Preservation during in-use storage
• Flavor stability
• Container compatibility
• Consistent delivery from the dosing cup or bottle

The formulation should be screened against anionic surfactants, anionic polymers, reactive flavor constituents, and high-peroxide excipients. Compatibility testing should include accelerated stability, freeze-thaw exposure, light exposure, agitation, and in-use bottle opening.

2. Develop an alcohol-free platform

An alcohol-free version is the clearest product-positioning opportunity. Potential commercial advantages include:

• Improved acceptance among patients sensitive to burning sensations
• Greater appeal to pediatric dental practices, subject to age-appropriate labeling
• Use in alcohol-avoidant patient populations
• Differentiation from conventional Peridex-type formulations
• Potential institutional demand where alcohol-containing rinses are undesirable

Removing alcohol can affect flavor solubilization, viscosity, precipitation behavior, microbial control, and sensory performance. The excipient system may require a revised solubilizer combination, higher glycerin content, alternative flavor delivery, or a different packaging configuration.

An alcohol-free version cannot be treated as a simple line extension. A change in inactive ingredients can require regulatory evaluation, comparative performance work, and potentially a supplement or separate abbreviated application depending on the approved product and the nature of the change.

3. Use flavor as a commercial asset

Flavor is more commercially important than color. Potential concepts include:

Flavor strategy	Target customer	Main risk
Mild mint	General dental market	Limited differentiation
Low-intensity mint	Sensitive patients	Lower perceived freshness
Alcohol-free mint	Patient-comfort segment	Solubility and aftertaste
Neutral or unflavored	Institutional and specialty use	Poor patient acceptance
Pediatric-oriented flavor	Pediatric dentistry	Safety, age labeling, and taste preferences

Flavor development must account for chlorhexidine’s persistent bitter and medicinal taste. High-intensity flavoring can increase sensory irritation and create instability if essential oils or terpene-rich components are used. A successful program should evaluate both immediate taste and delayed aftertaste, since chlorhexidine binds to oral tissues and can produce a prolonged sensory effect.

4. Consider color-free and low-staining positioning

Chlorhexidine itself is associated with tooth and tongue staining during use. Removing FD&C Blue No. 1 will not eliminate chlorhexidine-related staining, but it can support a cleaner product profile and reduce concern about unnecessary colorants.

A color-free formulation may have value in:

• Dental clinics serving patients with colorant sensitivities
• Hospital formularies
• Consumer-preference segments
• Private-label products positioned around minimal excipients

The claim must remain narrow. A color-free product should not imply reduced chlorhexidine staining unless supported by clinical evidence.

5. Optimize the package and dispensing system

Packaging is a practical source of differentiation. Commercial options include:

• 473 mL and 500 mL bottles for routine prescription use
• Unit-dose cups or sachets for hospitals and dental offices
• Child-resistant packaging
• Tamper-evident closures
• Metered-dose dispensers
• Multi-pack institutional configurations

The package must limit evaporation, leakage, microbial ingress, and adsorption or interaction with chlorhexidine. Compatibility studies should assess the bottle, cap liner, dosing cup, printed label, adhesives, and any elastomeric components. High-density polyethylene is common for oral liquids, but the preferred package depends on the approved container-closure system and extractables and leachables data.

What patents protect chlorhexidine gluconate 0.12% oral rinse?

The core chlorhexidine gluconate oral-rinse concept is mature and does not present a meaningful composition-of-matter patent barrier for a current generic entrant.

The relevant intellectual-property categories are:

IP category	Current commercial significance
Chlorhexidine active ingredient	Core exclusivity expired
0.12% oral-rinse formulation	Legacy protection largely expired
Gingivitis method of use	Generally weak as a barrier to generic entry
Flavor system	May support narrow formulation claims if novel
Alcohol-free formulation	Potentially protectable only if claims include a technically meaningful formulation limitation
Packaging or dosing system	Possible design or utility protection, usually narrow
Manufacturing process	May protect process details but rarely blocks routine generic manufacture
Brand and trade dress	More relevant than patents for retail differentiation

Peridex was approved decades ago. Its original patent and regulatory exclusivity period do not provide an active market barrier comparable to a current small-molecule product with unexpired composition patents. FDA Orange Book analysis should focus on any patents listed against the specific reference product and whether those patents remain unexpired. (FDA, n.d.-a; FDA, n.d.-c)

What is the Orange Book status of chlorhexidine gluconate oral rinse?

Chlorhexidine gluconate 0.12% oral rinse is an established small-molecule generic category associated with the Peridex reference product. The commercial pathway is an ANDA referencing the relevant FDA-listed reference product, subject to FDA requirements for pharmaceutical equivalence, bioequivalence or applicable product-specific evidence, labeling, and manufacturing controls.

The Orange Book analysis should address:

1. The precise reference-listed drug.
2. The dosage form and strength.
3. The therapeutic-equivalence code.
4. Any listed patents or regulatory exclusivities.
5. Whether the applicant is required to submit Paragraph I, II, III, or IV patent certifications.

Because this product category is old and broadly genericized, Paragraph IV litigation risk is generally lower than for recently approved branded drugs. A Paragraph IV certification remains legally possible if an applicant identifies an unexpired listed patent, but the commercial significance depends on the patent’s claim scope and remaining term.

When does chlorhexidine gluconate oral rinse lose exclusivity?

The principal exclusivity period has already elapsed. The market is now characterized by generic competition rather than by expected loss of exclusivity.

Milestone	Commercial effect
Original Peridex approval	Established the reference product
Expiration of original patent protection	Opened the category to generic development
Expiration of regulatory exclusivity	Enabled ANDA competition
Generic approvals	Shifted competition toward price, supply, flavor, and contracting
Current market	Mature generic oral-rinse category

No biosimilar exclusivity applies. Chlorhexidine gluconate is not a biologic, and the product is not subject to the Biologics Price Competition and Innovation Act pathway.

Which companies are challenging the chlorhexidine oral-rinse market?

The competitive field consists primarily of:

• Generic pharmaceutical manufacturers
• Dental-product manufacturers
• Contract manufacturers
• Private-label suppliers
• Hospital and group-purchasing distributors
• Branded suppliers retaining dental-office relationships

Competition is less likely to center on a single high-value patent challenge. It is more likely to arise through:

• Wholesale acquisition cost
• Contract pricing
• Supply reliability
• FDA shortage avoidance
• Bottle and dosing configurations
• Alcohol-free formulations
• Flavor acceptance
• Dental distributor access
• Formulary placement

The most defensible commercial position is not a basic undifferentiated 0.12% bottle. It is a reliable supply platform with a clear excipient or delivery advantage.

What formulation patents could create a commercial opportunity?

A formulation patent would need a credible technical distinction. Broad claims covering chlorhexidine, water, glycerin, flavor, and sweetener would face substantial validity and prior-art pressure.

More plausible claim targets include:

Alcohol-free solubilization systems

A novel combination of nonionic solubilizers, humectants, flavor components, and pH controls could support narrower claims if it produces a demonstrated stability or sensory benefit.

Low-staining systems

A formulation that reduces chlorhexidine-associated staining without reducing antimicrobial activity could have commercial value, but it would require controlled clinical or laboratory evidence.

Sustained-retention delivery

Mucoadhesive or controlled-contact systems could extend oral retention. This would move the product away from a conventional rinse and increase regulatory and development complexity.

Unit-dose delivery

A stable, low-waste unit-dose system could be protected through packaging, dosing, or combination claims. The commercial value would be highest in hospitals, dental offices, and procedural settings.

Pediatric or sensitive-mouth formulations

A low-irritancy, alcohol-free, low-flavor system may provide a differentiated product profile. Patentability would depend on technical limitations rather than marketing language alone.

How strong is the patent estate for DASH chlorhexidine gluconate oral rinse?

The patent estate is weak as a barrier to generic market entry and potentially useful only for incremental product improvements.

Factor	Assessment
Active-ingredient protection	Low
Basic 0.12% rinse protection	Low
Method-of-use protection	Low to moderate, depending on claim scope
Excipient-platform protection	Low for conventional excipients
Alcohol-free formulation opportunity	Moderate if technically novel
Packaging protection	Moderate but narrow
Freedom-to-operate risk	Generally manageable
Litigation exposure	Lower than for recently launched branded products

The strongest protection is likely to come from trade secrets covering flavor systems, process controls, supplier qualification, and stability know-how rather than from broad composition patents.

What generic launch risks exist for DASH chlorhexidine rinse?

Generic launch risk is primarily operational and regulatory.

Regulatory risks

• Inactive-ingredient differences that affect safety or performance
• Failure to demonstrate stability
• Inadequate microbial controls
• Incomplete container-closure data
• Labeling differences from the reference product
• Unresolved Orange Book patent certifications
• Manufacturing-site inspection findings

Technical risks

• Precipitation after storage
• Color or odor drift
• Flavor loss
• Chlorhexidine adsorption to packaging
• Assay decline
• Microbial contamination after opening
• Inconsistent dosing from the supplied cup

Commercial risks

• Low market price
• Dental distributor concentration
• Substitution by competing generic products
• Limited formulary differentiation
• Reliance on a single active or excipient supplier
• Low switching motivation among dentists and pharmacies

How does DASH compare with Peridex and other generic chlorhexidine rinses?

Attribute	DASH product	Peridex reference product	Other generic rinses
Active ingredient	Chlorhexidine gluconate	Chlorhexidine gluconate	Chlorhexidine gluconate
Strength	0.12%	0.12%	Commonly 0.12%
Regulatory role	Generic product	Reference product	Generic products
Patent barrier	Limited	Legacy estate	Limited
Differentiation	Excipient, flavor, supply, package	Brand recognition and clinical familiarity	Price and distribution
Biosimilar risk	None	None	None
Main customer	Pharmacies, dentists, institutions	Dental prescribers and established accounts	Pharmacies, wholesalers, institutions

DASH can compete effectively if it offers dependable supply, competitive pricing, and a meaningful sensory or packaging advantage. A conventional copy without channel access is likely to face margin compression.

What licensing and partnership opportunities exist?

The most practical licensing opportunities are commercial rather than patent-driven.

Potential partners include:

• Dental distributors
• Group purchasing organizations
• Pharmacy wholesalers
• Dental service organizations
• Hospital systems
• Contract manufacturers with oral-liquid capacity
• Flavor houses with oral-care expertise
• Packaging suppliers with unit-dose systems

A licensing or supply agreement could focus on:

1. An alcohol-free formulation.
2. A proprietary flavor system.
3. A unit-dose package.
4. A private-label dental product.
5. Regional distribution rights.
6. Hospital and institutional supply.
7. Co-development of a low-staining or low-irritancy version.

The value of a deal will depend more on demonstrated stability, customer contracts, and manufacturing capacity than on broad chlorhexidine patent claims.

What revenue exposure and market opportunities exist?

The product has recurring demand because gingivitis treatment generates repeat prescriptions, dental-office dispensing, and institutional consumption. Revenue exposure is still limited by generic pricing and substitution.

The most attractive segments are:

• Dental service organizations seeking standardized procurement
• Hospitals and outpatient surgery centers
• Public dental programs
• Medicaid and government tenders
• Retail pharmacies with generic substitution
• Dental offices requiring office-dispensed rinse
• Patients seeking alcohol-free or lower-irritancy products

The strongest margin opportunity is likely in differentiated formats rather than in standard large-volume bottles. Unit-dose packaging can command higher net pricing, but its economics depend on packaging cost, waste reduction, and institutional purchasing terms.

What is the recommended commercial strategy?

A staged strategy is preferable:

Phase 1: Defend the base product

Maintain the approved formulation, qualify multiple suppliers, validate package compatibility, and secure pharmacy and dental distribution.

Phase 2: Launch a differentiated extension

Prioritize an alcohol-free, mild-flavor product with a clear patient-comfort position. Avoid unsupported claims about reduced staining, superior antimicrobial activity, or improved clinical outcomes.

Phase 3: Pursue institutional formats

Develop unit-dose and larger-volume configurations for dental offices, hospitals, and group purchasing contracts.

Phase 4: Build narrow IP protection

File only where the formulation or package has a measurable technical advantage. Use trade-secret protection for flavor composition, processing parameters, and supplier specifications.

Phase 5: Expand geographically

The United States offers the clearest ANDA-based route. International expansion requires separate assessment of chlorhexidine concentration limits, prescription status, excipient permissions, labeling, pediatric restrictions, and local registration pathways. European and other markets may apply different rules to oral antiseptics and may not recognize the U.S. approval pathway.

Key Takeaways

• DASH Chlorhexidine Gluconate 0.12% Oral Rinse is a mature generic prescription oral-rinse product.
• The basic active ingredient and conventional rinse formulation have limited remaining patent value.
• The principal technical issue is chlorhexidine compatibility with anionic excipients, flavor components, and packaging materials.
• An alcohol-free, mild-flavor formulation is the strongest near-term differentiation opportunity.
• Color-free, low-waste, metered-dose, and unit-dose formats can support targeted commercial positioning.
• Biosimilar risk does not apply.
• Paragraph IV risk is likely lower than in recently approved branded drug categories, but the current Orange Book record must control the final certification analysis.
• Commercial success will depend on pricing, reliable supply, dental distribution, institutional contracts, and patient acceptance.
• Incremental patents may protect a novel formulation or package, but trade secrets and channel access are likely to provide more practical value.

FAQs

Can chlorhexidine gluconate 0.12% oral rinse be reformulated without alcohol?

Yes, but alcohol removal can affect flavor solubilization, stability, microbial control, viscosity, and sensory performance. The revised formulation requires regulatory and stability assessment before commercialization.

Is chlorhexidine gluconate oral rinse protected by an active composition patent?

The core chlorhexidine gluconate 0.12% oral-rinse platform is an established generic category with no apparent commercially meaningful composition-of-matter barrier. Any remaining listed patent must be reviewed against the specific reference product and current Orange Book record.

Can sodium lauryl sulfate be used in a chlorhexidine oral rinse?

Sodium lauryl sulfate is a poor default choice because it is an anionic surfactant that may interfere with cationic chlorhexidine. Any use would require compelling compatibility and antimicrobial-performance data.

Does removing FD&C Blue No. 1 reduce chlorhexidine tooth staining?

Not necessarily. Removing the colorant can support a color-free product position, but chlorhexidine-associated staining is linked primarily to the active ingredient and oral exposure.

Is a chlorhexidine oral rinse eligible for biosimilar competition?

No. Chlorhexidine gluconate is a small-molecule active ingredient. Competing products enter through generic-drug pathways rather than the biosimilar pathway.

References

1. DailyMed. (n.d.). Chlorhexidine gluconate oral rinse labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.-b). Peridex chlorhexidine gluconate oral rinse prescribing information. https://www.accessdata.fda.gov/

4. U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly purified synthetic peptides. https://www.fda.gov/್ರೆ